Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sucampo Pharma Inc (SCMP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 849,060
  • Shares Outstanding, K 47,170
  • Annual Sales, $ 230,060 K
  • Annual Income, $ 18,490 K
  • 36-Month Beta 1.38
  • Price/Sales 3.25
  • Price/Cash Flow 7.47
  • Price/Book 21.18
  • Price/Earnings ttm 12.33
  • Earnings Per Share ttm 1.46
  • Most Recent Earnings 0.27 on 11/01/17
  • Next Earnings Date 03/14/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.85 +1.12%
on 01/24/18
18.30 -1.37%
on 01/17/18
unch (unch)
since 01/12/18
3-Month
10.10 +78.71%
on 11/16/17
18.75 -3.73%
on 01/08/18
+7.75 (+75.24%)
since 11/13/17
52-Week
9.30 +94.09%
on 04/18/17
18.75 -3.73%
on 01/08/18
+6.55 (+56.96%)
since 02/13/17

Most Recent Stories

More News
Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, Inc.

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has closed the acquisition of Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, including...

SCMP : 18.05 (+0.28%)
MNK : 16.11 (+1.19%)
60.9% Return Seen to Date on SmarTrend Sucampo Pha-Cl A Call (SCMP)

SmarTrend identified an Uptrend for Sucampo Pha-Cl A (NASDAQ:SCMP) on November 28th, 2017 at $11.18. In approximately 2 months, Sucampo Pha-Cl A has returned 60.85% as of today's recent price of $17.98....

SCMP : 18.05 (+0.28%)
Quotidian Technical Highlights on Selected Drug Makers Stocks -- Novo Nordisk, Sucampo Pharma, Synergy Pharma, and Teva Pharmaceutical Industries

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on NVO, SCMP, SGYP, and TEVA which can be accessed for free by signing up to www.wallstequities.com/registration....

SCMP : 18.05 (+0.28%)
NVO : 53.79 (+1.38%)
TEVA : 19.99 (+0.96%)
SGYP : 1.88 (+1.08%)
Alexion's (ALXN) Earnings and Sales Beat Estimates in Q4

Alexion (ALXN) surpass earnings and sales estimates in the fourth quarter of 2017. The company received FDA approval for label expansion of Soliris in the United States.

XOMA : 25.94 (+2.33%)
SCMP : 18.05 (+0.28%)
EXEL : 29.34 (+0.82%)
ALXN : 118.38 (+3.31%)
Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down

Keryx (KERX) reports wider-than-expected loss in Q4. However, sales surpassed estimates.

XOMA : 25.94 (+2.33%)
KERX : 5.05 (+2.43%)
SCMP : 18.05 (+0.28%)
EXEL : 29.34 (+0.82%)
Boyd Gaming Set to Join S&P MidCap 400; Ring Energy, James River Group Holdings and EVERTEC to Join S&P SmallCap 600

S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600:

CUDA : 27.54 (unch)
EVTC : 16.73 (+0.48%)
CAA : 53.12 (+0.78%)
LEN : 59.05 (+1.06%)
SCMP : 18.05 (+0.28%)
JRVR : 34.55 (-10.35%)
REI : 14.50 (-2.16%)
SPGI : 191.07 (+1.71%)
MNK : 16.11 (+1.19%)
BYD : 35.27 (+3.58%)
Pfizer Files for Xtandi in Early Stage Prostate Cancer

Pfizer (PFE) announces detailed results from a late-stage study which can expand the label of Xtandi to include early-stage patients. It also files for approval in U.S. and EU.

XOMA : 25.94 (+2.33%)
SCMP : 18.05 (+0.28%)
EXEL : 29.34 (+0.82%)
PFE : 36.19 (+1.26%)
Sucampo Pha-Cl A Shares Up 60.9% Since SmarTrend's Buy Recommendation (SCMP)

SmarTrend identified an Uptrend for Sucampo Pha-Cl A (NASDAQ:SCMP) on November 28th, 2017 at $11.18. In approximately 2 months, Sucampo Pha-Cl A has returned 60.85% as of today's recent price of $17.98....

SCMP : 18.05 (+0.28%)
Novo Nordisk (NVO) Misses Q4 Earnings Estimates, Sales Beat

Novo Nordisk's (NVO) top-line growth was backed by growth in new-generation insulin, Victoza, Saxenda, and haemophilia products.

XOMA : 25.94 (+2.33%)
SCMP : 18.05 (+0.28%)
NVO : 53.79 (+1.38%)
EXEL : 29.34 (+0.82%)
Theravance's NDA for COPD Candidate Gets FDA Acceptance

The FDA accepts the new drug application for Theravance (TBPH) and partner Mylan's COPD candidate, revefenacin. A response on the same is expected on Nov 13, 2018.

TBPH : 27.79 (+2.77%)
XOMA : 25.94 (+2.33%)
SCMP : 18.05 (+0.28%)
EXEL : 29.34 (+0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products - AMITIZA, its lead product, and RESCULA - and a late-stage pipeline of product candidates in clinical...

See More

Key Turning Points

2nd Resistance Point 18.14
1st Resistance Point 18.07
Last Price 18.05
1st Support Level 17.94
2nd Support Level 17.88

See More

52-Week High 18.75
Last Price 18.05
Fibonacci 61.8% 15.14
Fibonacci 50% 14.02
Fibonacci 38.2% 12.91
52-Week Low 9.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.